



KODY TECHNOLAB LIMITED

Date: 12th March, 2026

To,
National Stock Exchange of India Limited
"Exchange Plaza", C-1, Block G,
Bandra-Kurla Complex,
Bandra (East),
Mumbai – 400 051

Dear Sir / Madam,

Sub: Intimation of Product Launch under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Security Id: KODYTECH / Series: ST

Pursuant to Regulation 30 read with Schedule III Part A Para B of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that Company is going to launch a new product i.e. "Medigo" AI-powered health screening robot. "Medigo" is a robotic-driven health screening infrastructure built to expand how preventive healthcare is delivered. "Medigo is designed as a single integrated system, it combines intelligent robotics, connected diagnostic devices and a unified software layer to enable structured screening in high-footfall environments.

These are also being made available on the website of the Company at <https://kodytechnolab.com/>

The details required under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 Annexure A.

Kindly take the same on your record and oblige us.

Thanking You.

For, Kody Technolab Limited

M. S. Patel

Manav Patel
Managing Director
DIN: 07409757



Registered Office Address: 2nd Floor, Block-J, Safal Mondeal Retail Park, Nr. Iscon Mall, Nr. Rajpathclub, S.G.Highway, Bodakdev, Ahmedabad, Gujarat - 380054

Work Address: Unit no. G01, ground floor, BIFC, building no. 14-A, block 14, zone-01, GIFT SEZ, Gandhinagar - 382355

Email: info@kodytechnolab.com | Contact No: +919377229944 | Website: www.kodytechnolab.com

CIN: L72900GJ2017PLC097244



KODY TECHNOLAB LIMITED

Annexure - A

Details as required under Regulation 30 of the Listing Regulations and the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are provided below:

Sr. No.	Particulars	Details
1.	Name of the product	"Medigo" AI-powered health screening robot
2.	Date of Launch	12 th March, 2026
3.	Category of the Product	Healthcare robot
4.	Whether it caters to domestic/ international market	Both
5.	Name of the countries in which the product is launched (in case of international)	Not Applicable

**Registered Office Address: 2nd Floor ,Block-J, Safal Mondeal Retail Park, Nr. Iscon Mall, Nr. Rajpathclub,
S.G.Highway, Bodakdev, Ahmedabad, Gujarat - 380054**

**Work Address: Unit no. G01, ground floor, BIFC, building no. 14-A, block 14, zone-01, GIFT SEZ,
Gandhinagar - 382355**

Email: info@kodytechnolab.com | Contact No: +919377229944 | Website: www.kodytechnolab.com

CIN: L72900GJ2017PLC097244



Product Innovation Announcement

INTRODUCING MEDIGO

The AI-Powered Autonomous Health Screening Robot

Democratizing Preventive **Healthcare for 5 Billion Underserved People** Worldwide

65+ Conditions Screenable	3 Min* Report Time	95% Screening Accuracy	Multi Languages Supported
-------------------------------------	------------------------------	----------------------------------	-------------------------------------

March 2026



01 | EXECUTIVE SUMMARY

Kody Technolab Limited is proud to announce Medigo as **an autonomous, AI-powered health screening robot** that represents a fundamental reinvention of how preventive healthcare can be delivered at scale. This is not an incremental product improvement. It is a ground-up re-engineering of healthcare access infrastructure, purpose-built for the 5+ billion people in developing economies who today have no reliable pathway to early disease detection.

Medigo can screen over 65 distinct medical conditions, generate a comprehensive health report in approximately 3 minutes, interact with patients in their native language, and instantly deliver results via WhatsApp, SMS, email, or printed report. A built-in telemedicine module enables real-time video consultation with a physician and instant prescription; all within a single, self-contained unit that requires no specialized medical staff to operate.

For governments, Medigo is a fiscal and public health multiplier: one machine creates the screening capacity of an entire primary care clinic, at a fraction of the cost, deployed anywhere: a rural village health centre, a railway station, a corporate campus, or a government hospital waiting room. The centralized data architecture provides health authorities with real-time regional disease surveillance, resource allocation intelligence, and early-warning epidemic detection that no existing infrastructure can match.

Medigo is the product of Kody Technolab Limited's decade-long investment in AI, hardware engineering, and enterprise software development, and it arrives at the precise intersection of **three powerful global tailwinds**: the exponential maturation of medical AI, a post-pandemic global urgency to build resilient health infrastructure, and a preventive healthcare market that is structurally shifting from treatment to early detection.



02 | THE PROBLEM

A BROKEN INFRASTRUCTURE SERVING BILLIONS

The Global Healthcare Access Gap

The foundational failure of healthcare in developing economies is not a shortage of doctors; it is a catastrophic absence of diagnostic infrastructure. Across South Asia, Sub-Saharan Africa, Southeast Asia, and Latin America, the journey from symptom to diagnosis can span weeks, require travel of hundreds of kilometres, and cost more than a month's household income. The inevitable result: diseases that are trivially treatable when caught early [Diabetes, Hypertension, HIV, Malaria, Tuberculosis, Cardiac Arrhythmias] are diagnosed only when they have become life-threatening, expensive to treat, and often irreversible.

The Cost Of Inaction

- The WHO estimates that **60%** of deaths in low- and middle-income countries are attributable to conditions that could have been identified and treated through early screening.
- Diabetes alone affects over **537 million** people globally; over **80%** of cases exist in low- and middle-income countries, where the majority remain undiagnosed.
- Cardiovascular disease, the **world's leading cause of death**, is almost entirely preventable with early detection, yet mass screening tools remain inaccessible to most of the world.
- Mental health conditions affect **1 in 8 people** globally; stigma and absence of accessible screening means the vast majority receive no support.
- TB kills **1.3 million** people annually, almost entirely in the developing world, despite being curable, the diagnostic barrier is the primary obstacle.

The Urban Acceleration Problem

While the rural gap is widely acknowledged, an equally urgent crisis is emerging in fast-growing urban centres across the developing world. Urban professionals face a paradox: healthcare facilities exist, but time does not. Preventive screening [blood panels, ECGs, lung function tests, vision and hearing assessments] requires booking appointments days in advance, visiting pathology labs, waiting for tests, and returning later for results. For the working population, this is practically prohibitive. Preventive care is therefore systematically deferred until acute symptoms force an emergency intervention, at dramatically higher cost.

The Data Blindspot

Health ministries across the developing world make critical resource allocation decisions for vaccine procurement, medication stockpiling, infrastructure investment with profoundly limited real-time data. Outbreak detection is reactive rather than predictive. Deficiency mapping [Vitamin D, Iron, Iodine] is conducted through expensive, infrequent national surveys. The intelligence that would allow governments to prevent crises rather than respond to them simply does not exist. **Medigo is designed to fill this blindspot permanently.**

03 | MEDIGO THE PRODUCT

[Watch Video](#)

What Medigo Is

Medigo is a robotics-driven health screening infrastructure built to expand how preventive healthcare is delivered. Designed as a single integrated system, it combines intelligent robotics, connected diagnostic devices, and a unified software layer to enable structured screening in high-footfall environments. A user begins the process through an AI-based guided interface in their preferred language, completes a series of connected diagnostic tests, and receives a consolidated health report in approximately 3 minutes. By standardizing how screenings are conducted and reported, Medigo brings preventive health screening out of episodic camps and into a scalable, deployable infrastructure for institutions, workplaces, and communities.

Core Screening Capabilities



Metabolic & Haematology

Diabetes (Blood Glucose, HbA1c), BMI & Body Composition, Liver Function, Kidney Function, Cholesterol Panel



Infectious Disease

HIV Screening, Malaria, RDT, TB Symptom Screening, Fever Surveillance, Pregnancy Test (UPT)



Systems & Vitals

Blood Pressure & ECG, Lung Efficiency, Vision Test, Hearing Test, Dental Check-up, Mental Health Assessments like ASD



03 | MEDIGO THE PRODUCT

AI Intelligence Layer



Multilingual Conversational AI

Understands patient-described symptoms in their native language and recommends the appropriate screening pathway.



Adaptive Protocol Engine

Dynamically prioritizes screening tests based on patient responses, demographics, and captured readings.



Clinical-grade Interpretation

AI models trained on large-scale validated clinical datasets analyze screening data to deliver high-accuracy results.



Post-result Analysis

Transforms screening data into clear, plain-language insights, highlighting critical values and recommended next steps.




Telemedicine Integration

Enables instant video consultation with physicians for real-time guidance and digital prescription issuance.

Delivery & Connectivity

- Reports delivered instantly via the patient's preferred channel, including WhatsApp, SMS, or email.
- On-site thermal printed report for patients without digital access.
- Centralized cloud data infrastructure: all screening data is transmitted securely to a government or institutional dashboard in real-time.
- Offline-capable architecture for deployment in areas with intermittent connectivity, with data synced when connection resumes.



04 | MARKET OPPORTUNITY

A TRILLION DOLLAR UNMET NEED

Total Addressable Market

The global preventive healthcare market was valued at approximately USD 268.7 billion in 2023 and is projected to reach **USD 585.6 billion** by 2030, growing at a **CAGR** of approximately **11.8%**. Within this, the diagnostic imaging and point-of-care testing segment [Medigo's most direct addressable space] was valued at USD 32.9 billion in 2025, is projected to reach **USD 34.5 billion** in 2026, and grow at a **CAGR** of **7.3%** through 2034. The AI in healthcare market is separately forecast to reach USD 187 billion by 2030, growing at a **CAGR** of **38.5%**.

Medigo's total addressable market is defined not by product category but by the healthcare access infrastructure gap it fills. Across India, Southeast Asia, Africa, Latin America, and the Middle East, there are approximately 2 million government-run primary health centres, 500,000+ corporate campuses, 1.5 million+ pharmacies and community health points, and thousands of transit infrastructure nodes [railway stations, airports, bus terminals] each a viable deployment location for a health screening infrastructure. At conservative unit economics, this represents a deployable fleet opportunity in the hundreds of billions of dollars.

Demand-Supply Gap: Where The Opportunity Lives

Current Supply (Status Quo)	Medigo: Closing The Gap
Doctor-to-patient ratio in rural India: 1:10,000+	One Medigo unit provides screening capacity for 200+ patients per day
Average lab report turnaround: 24–72 hours	Medigo generates 65+ condition reports in 3 minutes*
Average diagnostic spend per screening episode: USD 30–120	Medigo target cost per screening: USD 2–8
Disease outbreak detection lag: 4–8 weeks	Real-time regional surveillance with AI-powered anomaly detection
Health data coverage in rural areas: <10% of population	Every screening adds to a continuously updated national health database

04 | MARKET OPPORTUNITY

A TRILLION DOLLAR UNMET NEED

Primary Target Markets

India

1.4 billion people, 600,000+ villages, doctor-to-patient ratios among the world's most strained. Government's Ayushman Bharat digital health mission creates a ready policy and procurement framework.

Sub-Saharan Africa

46 countries with the world's youngest and fastest-growing population, the highest burden of infectious disease, and healthcare infrastructure in acute deficit. Donor-funded procurement mechanisms (PEPFAR, Gavi, Global Fund) provide complementary funding pathways.

Southeast Asia

High mobile penetration, growing middle-class awareness of preventive health, and government-led digital health programs in Indonesia, Philippines, Vietnam, and Thailand.

MENA

GCC nations investing massively in Vision 2030-style healthcare transformation; North Africa facing classical access gap challenges.

Urban Enterprise

Corporations across all geographies increasingly mandating employee health and wellness programs. Medigo's 3 minute screening fits precisely into the corporate wellness infrastructure gap.

05 | THE GOVERNMENT PROPOSITION


HEALTHCARE INTELLIGENCE AT SCALE

Governments are Medigo's most powerful institutional customer, not merely as buyers of equipment, but as beneficiaries of a data infrastructure that fundamentally transforms their ability to manage population health. The value proposition operates across three dimensions:


1. Fiscal Efficiency: The ROI Of Prevention

The economics of preventive versus reactive healthcare are unambiguous. The World Bank estimates that every USD 1 invested in preventive health interventions yields USD 4–9 in long-term treatment cost savings. For a government health ministry deploying Medigo at scale, the cost calculus is compelling: the per-screening cost of Medigo is a fraction of the cost of a single hospital admission for a condition that could have been detected at Stage 1.


Diabetes



HIV



Tuberculosis (TB)



05 | THE GOVERNMENT PROPOSITION

HEALTHCARE INTELLIGENCE AT SCALE

2. Real-Time Disease Intelligence

Every screening conducted on a Medigo unit feeds into a centralized, encrypted government dashboard. The aggregate data creates a living, real-time map of population health; something no national health system in the developing world currently possesses with any meaningful coverage or timeliness.

The intelligence applications are transformative:

- **Regional Deficiency Mapping**

Iron, vitamin D, and nutritional deficiency hotspots identified in real-time, enabling targeted intervention rather than blanket national programs.

- **Epidemic Early Warning**

Unusual clustering of fever, respiratory, or infectious disease symptoms triggers automated alerts, enabling containment days or weeks before traditional surveillance would detect an outbreak.

- **Vaccination and Medication Procurement Optimization**

Real-time disease prevalence data enables just-in-time procurement rather than over-ordering or under-ordering based on historical estimates.

- **Program Impact Assessment**

Governments can measure the direct health outcomes of public health campaigns within days instead of years.


- **Policy Evidence Base**

Anonymized, high-coverage population health data provides a scientifically rigorous foundation for health policy decisions.

3. Reduced Burden On Secondary And Tertiary Care

Every condition caught at the primary screening stage is a patient who does not require emergency hospital admission, does not occupy a hospital bed, and does not generate a catastrophic medical bill that drives a family into poverty. Medigo functions as an intelligent, always-on triage layer that ensures secondary and tertiary healthcare resources are directed where they are most critically needed.

Preventable Disease Burden
Across African Regions



06 | STRUCTURAL TAILWINDS

WHY NOW

The Preventive Healthcare Megatrend

Global consumer behaviour around health is undergoing a structural shift, from reactive treatment to proactive monitoring. This shift is most visible in wearables and consumer health tech, but it runs far deeper. Post-COVID, awareness of personal health baseline [blood pressure, blood sugar, lung function, immunity markers] has moved from the domain of the chronically ill to a mainstream expectation. The global wellness economy, valued at **USD 5.6 trillion** in 2022, is a leading indicator of where healthcare demand is heading: toward continuous, accessible, self-directed screening.

This shift is not limited to affluent markets. In developing economies, the growing middle class is acutely aware of the health risks associated with sedentary urban lifestyles, processed food consumption, and occupational stress. Non-communicable diseases [diabetes, hypertension, heart disease] which were historically the diseases of wealthy nations, are now epidemic in developing economies. The demand for affordable, convenient preventive screening is intense, and structurally underserved.

AI: From Aspiration To Clinical Reality

The convergence of large-scale medical datasets, transformer-based AI architectures, and affordable edge computing has, for the first time, made AI-powered clinical-grade diagnostics feasible outside of major hospital centres. Medigo is not a demonstration of AI's potential in healthcare, it is a deployment of AI that has crossed the clinical accuracy threshold (95%) required for real-world screening utility. The tailwind behind this is structural: the cost of compute continues to fall exponentially while the capability of medical AI models continues to compound. Every year, Medigo gets more capable without a hardware upgrade, through over-the-air model updates.

Government Digital Health Investment

The post-pandemic policy landscape has produced unprecedented government commitment to digital health infrastructure. India's Ayushman Bharat Digital Mission, the African Union's digital health strategy, WHO's Global Strategy on Digital Health, and the World Bank's health digitisation lending programs collectively represent hundreds of billions of dollars in committed public investment. Medigo is precisely positioned to be a flagship deployment within these frameworks; a tangible, measurable expression of digital health infrastructure that produces visible outcomes at the community level.

Hardware-AI Convergence

The last five years have produced dramatic improvements in the cost, size, and capability of the hardware components that Medigo integrates: miniaturized biosensors, high-accuracy point-of-care diagnostic cartridges, low-power AI inference chips, and high-resolution imaging components. What required a fully equipped hospital laboratory a decade ago can now be housed in a single unit at a cost that enables mass deployment. This hardware convergence is a non-reversible structural shift, and Kody Technolab Limited's R&D team has systematically positioned itself to capitalize on it.

07 | **KODY TECHNO LAB**

THE CAPABILITY BEHIND THE PRODUCT

Medigo did not emerge from a pivot or an opportunistic market bet. It is the natural expression of a decade of compounding investment in AI engineering, hardware integration, and enterprise-scale software development. Understanding the product requires understanding the organization that built it.

AI & Machine Learning Engineering

Kody Technolab Limited's AI team has deep experience in building and deploying production-grade ML systems across computer vision, natural language processing, and time-series analytics. The multilingual conversational interface, the adaptive screening protocol engine, the clinical result interpretation layer, and the centralized anomaly detection dashboard are each the product of sustained, proprietary AI development; not off-the-shelf integration. The team's ability to train, fine-tune, and deploy medical AI models on validated clinical datasets represents a genuine and defensible technical moat.

Hardware-Software Integration

The engineering challenge of Medigo is not the software or the hardware in isolation, it is the seamless integration of biosensors, diagnostic modules, imaging systems, and AI inference within a single unit that is robust, field-serviceable, and manufacturable at scale. This system's integration capability, combining mechanical design, embedded systems, firmware, and cloud connectivity; is rare, and it is a core strength of Kody Technolab Limited's engineering organization.

Enterprise-Scale Product Development

Kody Technolab Limited has an established track record of building complex, enterprise-grade technology products across healthcare, fintech, logistics, and government verticals. The organizational maturity to navigate regulatory requirements, build for data security and sovereignty at the government level, and deliver products that operate reliably in low-bandwidth, high-humidity, high-usage field environments is a capability built over years, and it is directly applicable to Medigo's deployment context.

R&D Philosophy: Innovating At The Fundamental Level

Kody Technolab Limited's R&D approach is characterized by a commitment to innovating at the component level rather than assembling existing solutions. The result is a product architecture that is not dependent on third-party black boxes: from the AI models and the data pipeline to the diagnostic protocols and the reporting engine, the core technology is proprietary. This matters enormously for long-term defensibility, cost structure, and adaptability as market requirements evolve.

08 | CLOSING

THE OPPORTUNITY IN FRONT OF US

The world is at an inflection point in healthcare. The technology to screen, detect, and prevent the diseases that kill and impoverish hundreds of millions of people in the developing world exists. The political will to invest in health infrastructure is higher than it has been in a generation. The economic case for prevention over treatment is overwhelming.

What has been missing is the infrastructure that turns prevention into practice. **Medigo is engineered to provide that infrastructure.**

Kody Technolab Limited has spent years building the AI capability, the engineering depth, and the domain understanding required to create it. They built it from the ground up, with a precise understanding of the environments it will be deployed in, the populations it will serve, and the governments it will partner with.

The total addressable market is measured in hundreds of billions of dollars. The social impact is measured in millions of lives. The defensibility of the position we are building [proprietary AI, centralized government data infrastructure, and a growing installed base] compounds with every deployment.

We are at the beginning of building one of the most significant health infrastructure companies in the emerging world.



For inquiries about Medigo, please contact:

info@kodytechnolab.com

www.kodytechnolab.com

This document is a product announcement for informational and awareness purposes only and may contain forward-looking statements. Market data sourced from WHO, the World Bank, Grand View Research, and IQVIA. Subject to applicable regulatory approvals.